Filing Flows › Health Care › Atrium Therapeutics (RNA)
Atrium Therapeutics (RNA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Atrium Therapeutics (RNA) Q2 2026 earnings results →
Q2 2026 Revenue down 22% year over year to $3.0M · 672¢ of every $1 of revenue lost · operating margin -752.9%
Atrium Therapeutics made $3.0M in Q2 2026 (-22% Y/Y). Operating margin -752.9%, net loss $20.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.0M in Q2 2026, down 22% year over year and down 85% from the previous quarter.
Operating costs exceeded revenue by $22.6M, an operating margin of -752.9%. Total costs grew 53% against a revenue fall of 22%. The fastest-growing cost line was General & admin (+201%). The quarter ended with a net loss of $20.2M, wider than the previous quarter's $16.6M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $343K of depreciation and $893K of share-based compensation. Working capital and other items added $15.0M. Capital expenditures of $36K exceeded it, leaving free cash flow of −$4.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $3.0M | -22% | -752.9% | −$20.2M | −$3.9M |
| Q1 2026 | 10-Q | May 14, 2026 | $19.6M | 12× | -88.0% | −$16.6M | −$31.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration’s (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company’s proprietary technology - designed at Avidity Biosciences, Inc.
In its own words, from its 8-K, filed Aug 13, 2026.
Atrium Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -22% against the peers' median +7%. Operating margin: -752.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RNA Atrium Therapeutics | Q2 2026 | $3.0M | -22% | -752.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Atrium Therapeutics 10-Q on SEC EDGAR · CIK 2093101 · Pharmaceutical Preparations
13F: who owns RNA and who is buying
More on RNA
- How Atrium Therapeutics makes money: revenue by segment
- Atrium Therapeutics next earnings date and what analysts expect
- Atrium Therapeutics stock forecast, price target and fair value
- Who owns Atrium Therapeutics stock: holders, funds and Congress trades
- Atrium Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results